Gyroscope, a clinical stage ophthalmology company, was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of age-related macular degeneration (AMD) and gene therapy as a mode of sustained treatment delivery.

Age-related macular degeneration is the leading cause of irreversible blindness in the elderly. Today there is no effective treatment for the atrophic form of the disease. Gyroscope’s global management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at multiple innovative biotech and pharmaceutical companies. Through their delivery system, Gyroscope also have significant surgical device development and surgeon training capabilities.

Gyroscope is developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (dry-AMD).

Merger with Orbit medical in June 2019